TriangleNCT00551070 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- pi Sponsor Employee
- false
- restriction Type
- LTE60
- restrictive Agreement
- true
- limitations And Caveats
- description
- Study began with 100mg BID mix \& drink (MD) formulation. AstraZeneca (AZ) switched to hydrogen-sulfate capsule (HC). AZ deemed 100mg BID MD equivalent to 50mg BID HC. As of 12/31/2010, patients got 50mg BID HC; four patients were on treatment then.
- point Of Contact
- kurasa@nrgoncology.org
- organization
- NRG Oncology Statistics and Data Management Center - Buffalo
- phone
- 716-845-7733
- title
- Angela M. Kuras, Associate Director of Data Management
Complete source fields
- certain Agreement
- pi Sponsor Employee
- false
- restriction Type
- LTE60
- restrictive Agreement
- true
- limitations And Caveats
- description
- Study began with 100mg BID mix \& drink (MD) formulation. AstraZeneca (AZ) switched to hydrogen-sulfate capsule (HC). AZ deemed 100mg BID MD equivalent to 50mg BID HC. As of 12/31/2010, patients got 50mg BID HC; four patients were on treatment then.
- point Of Contact
- kurasa@nrgoncology.org
- organization
- NRG Oncology Statistics and Data Management Center - Buffalo
- phone
- 716-845-7733
- title
- Angela M. Kuras, Associate Director of Data Management
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice